We’ve contributed to the successful approval of eight marketed cardiovascular and cardio-metabolic drugs.
Summary
PRA is globally involved in cardiovascular and cardio-metabolic drug development, having contributed to the successful approval of eight marketed cardio-metabolic drugs. Our ability to network with cardio-metabolic experts and investigators around the world—which comes from our extensive experience planning and executing cardiovascular studies—allows us to leverage established and new relationships for the benefit of our sponsors. We combine vast experience and expertise in this field, class-leading digital health architecture, and global infrastructure to design and deliver effective and efficient solutions across every facet of cardio-metabolic research. Above all, we craft the industry-leading patient journey—increasing access for potential participants, reducing the burden of participation, and enabling a truly patient-first experience throughout the entire journey.
Patients
45,300+Sites
3,000+CARDIO-METABOLIC STUDIES
53+NON-CLINICAL CARDIO-METABOLIC PROJECTS
16+More discoveries in store
Despite the advances in the cardio-metabolic field over the past 20 years, cardiovascular and metabolic diseases such as coronary artery disease, high blood pressure, diabetes, and dyslipidemia remain the leading causes of morbidity and mortality around the world. While there has been significant progress in the understanding of the pathophysiology and in patient management, the need to discover and develop better, safer drugs and devices to address patients’ needs remains.
Our cardiovascular/metabolic portfolio includes:
Cardiovascular
- Atrial and Ventricular Arrythmia
- Cardiomyopathy (e.g. ATTR, hypertrophic, etc. with rare disease team)
- Heart Failure
- Hypertension
- Pulmonary Hypertension (with respiratory team)
- Coronary Artery Disease and Stable Angina
- Acute Coronary syndromes, including myocardial infarction
- Venous Thromboembolism
- Peripheral Arterial Disease
Atherosclerotic & embolic cerebrovascular disease
- Stroke, TIA (with neurosciences team)
Metabolic
- Diabetes
- Dyslipidemia
- Hyperuricemia
Leveraging established relationships with leading investigators to build custom strategies
Our in-house therapeutic experts leverage their existing relationships with leading investigators and key opinion leaders in cardio-metabolic diseases to effectively recruit patients, manage sites, and support strategies tailored to meet your unique needs. We have a thorough understanding of standards of care and critical success factors, and our experts have experience in relatively rare indications, including pulmonary hypertension and acute peripheral arterial occlusion.
Diagnostic tools commonly used to confirm patient eligibility for enrollment or as study endpoints in PRA’s cardiovascular and cardiometabolic studies include:
- Echocardiography
- Electrocardiogram (ECG) and vital signs’ measurement (e.g. office and ambulatory blood pressure)
- Coronary CT Angiography (CCTA, including FFRCT)
- Cardiac Magnetic Resonance Imaging (MRI)
- Single Photon Emission Computed Tomography (SPECT) / Myocardial Stress Perfusion Imaging
- Diagnostic Heart Catheterization (including FFR)
- Exercise and functional capacity testing (e.g. cycle, treadmill, 6-minute walk test, cardiopulmonary exercise testing (CPET), treadmill, accelerometry, etc.)
Supporting type 1 and 2 diabetes research
With more than 25% of our cardio-metabolic work being in type 2 diabetes, we have the expertise to implement best practices and operational efficiencies for studies to succeed. We’ve conducted studies with more than 30 compounds developed for the treatment of type 1 or type 2 diabetes or metabolic syndrome, and the majority of our Phase I and II studies were performed in our clinical pharmacology units in the Netherlands and the US.
Read more about how we’ve met challenging recruitment goals for type 2 diabetes studies.Explore related content and topics
Blog
PRA Health Sciences and Deep Lens, Inc. partner to accelerate patient recruitment for precision cancer trials.
This strategic relationship brings together best-in-class technologies that improve the identification, screening, and matching of cancer patients to…
Case Study
Persistence Leads To High Enrollment
A Phase IV, randomized, single-blind, placebo-controlled, multi-center study to evaluate the immunogenicity of pneumococcal and influenza vaccines in…
White Paper
Strategies for Accelerating Rare Disease Clinical Development
Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient…